News Galderma adds new indication for blockbuster hope Nemluvio Galderma has claimed a second FDA approval for IL-31 inhibitor Nemluvio, adding atopic dermatitis to its label.
News Galderma gets FDA nod for prurigo nodularis therapy Dermatology specialist Galderma has FDA approval for prurigo nodularis treatment Nemluvio, one of two new drugs that it thinks will deliver blockbuster sales.
Market Access The changing landscape of drug clinical assessment: Tommy Br... In a new pharmaphorum podcast, Tommy Bramley, SVP of market access and healthcare consulting at Cencora, discusses Joint Clinical Assessments.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
